Investment House buys $8,309,726 stake in Amgen (AMGN)

Amgen (AMGN) : Investment House scooped up 223 additional shares in Amgen during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 25, 2016. The investment management firm now holds a total of 48,686 shares of Amgen which is valued at $8,309,726.Amgen makes up approximately 1.27% of Investment House’s portfolio.

Other Hedge Funds, Including , Jfs Wealth Advisors reduced its stake in AMGN by selling 17 shares or 3.29% in the most recent quarter. The Hedge Fund company now holds 500 shares of AMGN which is valued at $85,340. Amgen makes up approx 0.02% of Jfs Wealth Advisors’s portfolio.Mountain Pacific Investment Advisers Incid boosted its stake in AMGN in the latest quarter, The investment management firm added 441 additional shares and now holds a total of 3,072 shares of Amgen which is valued at $508,938. Amgen makes up approx 0.06% of Mountain Pacific Investment Advisers Incid’s portfolio. Hills Bank Trust Co sold out all of its stake in AMGN during the most recent quarter. The investment firm sold 4,800 shares of AMGN which is valued $783,600.Naples Global Advisors reduced its stake in AMGN by selling 125 shares or 0.78% in the most recent quarter. The Hedge Fund company now holds 15,920 shares of AMGN which is valued at $2,555,478. Amgen makes up approx 1.03% of Naples Global Advisors’s portfolio.Kistler-tiffany Companies reduced its stake in AMGN by selling 51 shares or 0.41% in the most recent quarter. The Hedge Fund company now holds 12,379 shares of AMGN which is valued at $1,994,257. Amgen makes up approx 1.01% of Kistler-tiffany Companies’s portfolio.

Amgen opened for trading at $171.57 and hit $172.26 on the upside on Friday, eventually ending the session at $172.03, with a gain of 0.44% or 0.75 points. The heightened volatility saw the trading volume jump to 31,21,594 shares. Company has a market cap of $129,232 M.

On the company’s financial health, Amgen reported $2.84 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $2.74. The company had revenue of $5688.00 million for the quarter, compared to analysts expectations of $5579.33 million. The company’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.57 EPS.

Investors should note that on Jul 22, 2016, Amgen announced a cash dividend of $1.0000. The company’s management has announced Aug 15, 2016 as the ex-dividend date and fixed the record date on Aug 17, 2016. The payable date has been fixed on Sep 8, 2016.

Many Wall Street Analysts have commented on Amgen. Amgen was Initiated by Bernstein to “Mkt Perform” on Jun 29, 2016.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *